Xeris Biopharma Holdings, Inc.
XERS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001867096
In the last 90 days, Xeris Biopharma Holdings, Inc. insiders filed 0 open-market purchases and 8 sales; 242 institutions reported holding it in 13F filings for Q2 2026, worth $857.1M in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in Xeris Biopharma Holdings, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 103
- +12 vs. Q4 2021
- Shares held
- 50.5M
- +9.44M (+23.0%) vs. Q4 2021
- Total value
- $129.2M
- +$8.99M (+7.5%) vs. Q4 2021
- New holders
- 27
- 33 more added
- Sold out
- 15
- 26 more reduced
1 institution that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XERS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 242 | $857.1M |
| Q1 2026 | 239 | $610.3M |
| Q4 2025 | 227 | $792.0M |
| Q3 2025 | 231 | $789.3M |
| Q2 2025 | 201 | $422.9M |
| Q1 2025 | 199 | $480.9M |
| Q4 2024 | 162 | $222.2M |
| Q3 2024 | 144 | $182.2M |
| Q2 2024 | 135 | $136.6M |
| Q1 2024 | 142 | $133.7M |
| Q4 2023 | 120 | $140.8M |
| Q3 2023 | 111 | $102.3M |
| Q2 2023 | 105 | $146.7M |
| Q1 2023 | 92 | $80.6M |
| Q4 2022 | 97 | $71.6M |
| Q3 2022 | 101 | $89.3M |
| Q2 2022 | 103 | $91.3M |
| Q1 2022 | 103 | $129.2M |
| Q4 2021 | 92 | $120.2M |
| Q3 2021 | 71 | $42.9M |
| Q2 2021 | 94 | $114.9M |
| Q1 2021 | 103 | $149.7M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Xeris Biopharma Holdings, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Caxton Corp | 6,039,028 | $15.5M | 19.22% | −271,518−4.3% | Reduced |
| Armistice Capital, LLC | 7,464,993 | $19.1M | 0.54% | +7,464,993 | New |
| Stonepine Capital Management, LLC | 7,924,056 | $20.3M | 8.41% | +2,267,683+40.1% | Added |
| IHT Wealth Management, LLC | 0 | $0 | 0.00% | −342,897−100.0% | Sold out |
| Aristides Capital LLC | 0 | $0 | 0.00% | −100,080−100.0% | Sold out |
| Kamunting Street Capital Management, L.P. | 0 | $0 | 0.00% | −64,539−100.0% | Sold out |
| GPS Wealth Strategies Group, LLC | 0 | $0 | 0.00% | −59,025−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −49,088−100.0% | Sold out |
| Caption Management, LLC | 0 | $0 | 0.00% | −47,600−100.0% | Sold out |
| Evercore Wealth Management, LLC | 0 | $0 | 0.00% | −38,801−100.0% | Sold out |
| Belvedere Trading LLC | 0 | $0 | 0.00% | −47,282−100.0% | Sold out |
| Leonteq Securities AG | 0 | $0 | 0.00% | −21,000−100.0% | Sold out |
| Avenue 1 Advisors, LLC | 0 | $0 | 0.00% | −12,544−100.0% | Sold out |
| Raymond James & Associates | 0 | $0 | 0.00% | −11,300−100.0% | Sold out |
| Aigen Investment Management, LP | 0 | $0 | 0.00% | −10,586−100.0% | Sold out |
| Paloma Partners Management Co | 0 | $0 | 0.00% | −10,066−100.0% | Sold out |
| TSFG, LLC | 0 | $0 | 0.00% | −5,488−100.0% | Sold out |
| Northwestern Mutual Wealth Management Co | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Sphinx Trading, LP | – | – | – | – | Not filed |